Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Memory Assessment and Research Centre, Moorgreen Hospital, Southern Health Foundation Trust, Southampton, UK.
Neuropathol Appl Neurobiol. 2024 Feb;50(1):e12965. doi: 10.1111/nan.12965.
In Alzheimer's disease (AD), the locus coeruleus (LC) undergoes early and extensive neuronal loss, preceded by abnormal intracellular tau aggregation, decades before the onset of clinical disease. Neuromelanin-sensitive MRI has been proposed as a method to image these changes during life. Surprisingly, human post-mortem studies have not examined how changes in LC during the course of the disease relate to cerebral pathology following the loss of the LC projection to the cortex.
Immunohistochemistry was used to examine markers for 4G8 (pan-Aβ) and AT8 (ptau), LC integrity (neuromelanin, dopamine β-hydroxylase [DβH], tyrosine hydroxylase [TH]) and microglia (Iba1, CD68, HLA-DR) in the LC and related temporal lobe pathology of 59 post-mortem brains grouped by disease severity determined by Braak stage (0-II, III-IV and V-VI). The inflammatory environment was assessed using multiplex assays.
Changes in the LC with increasing Braak stage included increased neuronal loss (p < 0.001) and microglial Iba1 (p = 0.005) together with a reduction in neuromelanin (p < 0.001), DβH (p = 0.002) and TH (p = 0.041). Interestingly in LC, increased ptau and loss of neuromelanin were detected from Braak stage III-IV (p = 0.001). At Braak stage V/VI, the inflammatory environment was different in the LC vs TL, highlighting the anatomical heterogeneity of the inflammatory response.
Here, we report the first quantification of neuromelanin during the course of AD and its relationship to AD pathology and neuroinflammation in the TL. Our findings of neuromelanin loss early in AD and before the neuroinflammatory reaction support the use of neuromelanin-MRI as a sensitive technique to identify early changes in AD.
在阿尔茨海默病(AD)中,蓝斑(LC)经历了早期和广泛的神经元丢失,在此之前,异常的细胞内 tau 聚集发生了几十年,远早于临床疾病的发生。神经黑色素敏感 MRI 已被提议作为一种在有生之年成像这些变化的方法。令人惊讶的是,人类死后研究尚未检查 LC 在疾病过程中的变化与 LC 投射到皮质后的大脑病理学之间的关系。
使用免疫组织化学方法检查 4G8(泛 Aβ)和 AT8(ptau)、LC 完整性(神经黑色素、多巴胺 β-羟化酶 [DβH]、酪氨酸羟化酶 [TH])和小胶质细胞(Iba1、CD68、HLA-DR)的标志物在 59 个死后大脑中进行检查,这些大脑根据 Braak 阶段(0-II、III-IV 和 V-VI)确定的疾病严重程度进行分组。使用多重分析评估炎症环境。
随着 Braak 阶段的增加,LC 发生的变化包括神经元丢失增加(p<0.001)和小胶质细胞 Iba1 增加(p=0.005),同时神经黑色素(p<0.001)、DβH(p=0.002)和 TH(p=0.041)减少。有趣的是,在 LC 中,从 Braak 阶段 III-IV 开始检测到增加的 ptau 和神经黑色素的丢失(p=0.001)。在 Braak 阶段 V/VI,LC 与 TL 中的炎症环境不同,突出了炎症反应的解剖异质性。
在这里,我们报告了 AD 过程中神经黑色素的首次定量及其与 TL 中 AD 病理学和神经炎症的关系。我们发现 AD 早期和神经炎症反应之前的神经黑色素丢失支持使用神经黑色素-MRI 作为一种敏感技术来识别 AD 的早期变化。